78511-92-9

Upstream product

• 3754-52-7 3'-iodo-5,7,4'-trimethoxyflavone 
• 1165-94-2 8-iodo-5,7-dimethoxy-2-(4-methoxyphenyl)-4H-chromen-4-one 
• 1617-53-4 amentoflavone 
• 77-78-1 dimethyl sulfate 
• 74-88-4 methyl iodide 
• 135159-25-0 (2,4,6-trimethoxyphenyl)boronic acid 
• 548-19-6 isoginkgetin 
• 135159-05-6 5,7-Dimethoxy-2-(6,2',4',6'-tetramethoxy-biphenyl-3-yl)-chromen-4-one 
• 21763-71-3 Sequoiaflavone 
• 135159-06-7 2-{2'-Hydroxy-6,4',6'-trimethoxy-3'-[(E)-3-(4-methoxy-phenyl)-acryloyl]-biphenyl-3-yl}-5,7-dimethoxy-chromen-4-one 

Downstream Products

• 3778-25-4 7,4',7'',4'''-tetra-O-methylamentoflavone 
• 90-24-4 2-hydroxy-4,6-dimethoxyacetophenone 
• 3187-19-7 2,4-dimethoxysalicylic acid 
• 107225-53-6 8-[5-(5,7-dimethoxy-4-hydroxyimino-4H-chromen-2-yl)-2-methoxy-phenyl]-5,7-dimethoxy-2-(4-methoxy-phenyl)-chromen-4-one oxime 

Relevant academic research and scientific papers

Structure-activity relationship study of biflavonoids on the dengue virus polymerase DENV-NS5 RdRp

Dengue virus is the worlds most prevalent human pathogenic arbovirus. There is currently no treatment or vaccine, and solutions are urgently needed. We previously demonstrated that biflavonoids from Dacrydium balansae, an endemic gymnosperm from New Caledonia, are potent inhibitors of the Dengue virus NS5 RNA-dependent RNA polymerase. Herein we describe the structure-activity relationship study of 23 compounds: biflavonoids from D. balansae (1-4) and from D. araucarioides (5-10), hexamethyl-amentoflavone (11), cupressuflavone (12), and apigenin derivatives (13-23). We conclude that 1) over the four different biflavonoid skeletons tested, amentoflavone (1) and robustaflavone (5) are the most promising ones for antidengue drug development, 2) the number and position of methyl groups on the biflavonoid moiety modulate their inhibition of Dengue virus NS5 RNA-dependent RNA polymerase, and 3) the degree of oxygenation of flavonoid monomers influences their antidengue potential. Sotetsuflavone (8), with an IC50 = 0.16 μM, is the most active compound of this series and is the strongest inhibitor of the Dengue virus NS5 RNA-dependent RNA polymerase described in the literature. Georg Thieme Verlag KG Stuttgart New York.

COMPOUNDS, COMPOSITION AND USES THEREOF FOR TREATING CANCER

The present invention relates to the fields of medicine and cancer treatment. The invention more specifically relates to new compounds which are typically for use as a medicament. In particular, the invention relates to the use of these new compounds for increasing the presentation, typically the production and presentation, of Pioneer Translation Products (PTPs)-derived antigens by cancer cells in a subject, and inducing or stimulating an immune response in the subject. The present disclosure also relates to uses of such compounds, in particular to prepare a pharmaceutical composition and/or to allow or improve the efficiency of a cancer therapy in a subject in need thereof. The invention also discloses methods for preventing or treating cancer, cancer metastasis and/or cancer recurrence in a subject. The present invention in addition provides kits suitable for preparing a composition according to the present invention and/or for implementing the herein described methods.

A new strategy for the synthesis of biflavonoids via arylboronic acids

Amentoflavone derivatives were prepared by catalytic coupling of 8-flavone-boronic acids with iodoflavones. 3-Arylflavones, as biflavonoid synthon, are accessible by the method.

FLAVONOID PROFILES OF NEW ZEALAND LIBOCEDRUS AND RELATED GENERA

Flavonoids common to both Libocedrus bidwillii and L. plumosa, which were sampled throughout New Zealand, are: kaempferol and quercetin 3-rhamnoside, kaempferol and quercetin 3-rhamnoside-7-glucoside, quercetin 3-glucoside, apigenin and luteolin 7-glucosi